Narumi Nakagiri
Stock Analyst at Daiwa Capital
(1.12)
# 3,520
Out of 4,734 analysts
10
Total ratings
40%
Success rate
-5.36%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Narumi Nakagiri
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ILMN Illumina | Upgrades: Buy | $120 → $154 | $141.31 | +8.98% | 1 | Aug 16, 2024 | |
| PFE Pfizer | Upgrades: Outperform | $28 → $34 | $26.64 | +27.63% | 3 | Aug 8, 2024 | |
| JNJ Johnson & Johnson | Downgrades: Neutral | $160 → $150 | $148.15 | +1.25% | 1 | Jul 23, 2024 | |
| AMGN Amgen | Upgrades: Buy | $320 | $274.81 | +16.44% | 2 | Dec 21, 2023 | |
| BMY Bristol-Myers Squibb Company | Downgrades: Neutral | $68 → $54 | $57.04 | -5.33% | 1 | Nov 2, 2023 | |
| MRK Merck & Co. | Upgrades: Outperform | $89 → $102 | $96.24 | +5.99% | 2 | Jul 7, 2022 |
Illumina
Aug 16, 2024
Upgrades: Buy
Price Target: $120 → $154
Current: $141.31
Upside: +8.98%
Pfizer
Aug 8, 2024
Upgrades: Outperform
Price Target: $28 → $34
Current: $26.64
Upside: +27.63%
Johnson & Johnson
Jul 23, 2024
Downgrades: Neutral
Price Target: $160 → $150
Current: $148.15
Upside: +1.25%
Amgen
Dec 21, 2023
Upgrades: Buy
Price Target: $320
Current: $274.81
Upside: +16.44%
Bristol-Myers Squibb Company
Nov 2, 2023
Downgrades: Neutral
Price Target: $68 → $54
Current: $57.04
Upside: -5.33%
Merck & Co.
Jul 7, 2022
Upgrades: Outperform
Price Target: $89 → $102
Current: $96.24
Upside: +5.99%